Skip to content

A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery

A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01296542
Enrollment
60
Registered
2011-02-15
Start date
2011-05-31
Completion date
2013-01-31
Last updated
2020-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataracts

Brief summary

To compare antibacterial efficacy of Besivance versus VIGAMOX for decreasing bacteria of the conjunctiva and lid margins in cataract patients prior to surgery after both 1 hour and 3 days of treatment.

Interventions

Sponsors

Bucci Laser Vision Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Man or woman 18 years of age or older. * Physically capable of instilling eye drop or have an appropriate person available to assist in administration of eye drops 4 times a day. * Scheduled for phacoemulsification with intraocular lens (IOL) implantation for the treatment of cataract. * Meet the American Society of Anesthesiology (ASA) physical status I, II, or III and be medically cleared for surgery. * Willing to adhere to the prohibitions and restrictions specified in this protocol. * Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion criteria

* Known allergy or contraindication to the test article(s) or their components. * Presence of any abnormality or significant illness in the eye that in the investigator's opinion could affect the subject's health or the study parameters. * Presence of an active ocular infection (bacterial, viral or fungal), or positive history of ocular herpetic infection. * History of any significant illness that could be expected to interfere with the study parameters. Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study. * Use of disallowed therapies (systemic or topical): * Fluoroquinolone anti-infective agents (systemic or topical) within 1 week of Visit 1 or anytime after Visit 1 for the duration of the study. * Use of contact lenses for one week prior to the study and for the duration of the study. * Received an experimental drug or used an experimental medical device within 21 days before the planned start of treatment.

Design outcomes

Primary

MeasureTime frameDescription
Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 DaysFollowing 3 days of antibiotic drops topically instilledLid and Conjunctival cultures will be taken to measure bacterial colonization.

Countries

United States

Participant flow

Participants by arm

ArmCount
VIGAMOX
Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
30
Besivance
Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
30
Total60

Baseline characteristics

CharacteristicVIGAMOXBesivanceTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
27 Participants23 Participants50 Participants
Age, Categorical
Between 18 and 65 years
3 Participants7 Participants10 Participants
Sex: Female, Male
Female
18 Participants16 Participants34 Participants
Sex: Female, Male
Male
12 Participants14 Participants26 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 300 / 28
serious
Total, serious adverse events
0 / 300 / 28

Outcome results

Primary

Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days

Lid and Conjunctival cultures will be taken to measure bacterial colonization.

Time frame: Following 3 days of antibiotic drops topically instilled

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
VIGAMOXNumber of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days18 Participants
BesivanceNumber of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days28 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026